Armata Pharmaceuticals/ARMP

$4.07

3.29%
-
1D1W1MYTD1YMAX

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

Ticker

ARMP

Sector

Healthcare

Trading on

AMEX

Industry

Biotechnology & Drugs

CEO

Deborah Birx

Employees

72

Headquarters

Los angeles, United States

ARMP Metrics

BasicAdvanced
$147.12M
Market cap
-
P/E ratio
-$1.65
EPS
0.86
Beta
-
Dividend rate

What the Analysts think about ARMP

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
96.56% upside
High $9.00
Low $7.00
$4.07
Current price
$8.00
Average price target

ARMP Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,591.66% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$1.2M
33.33%
Net income
$-31.1M
788.57%
Profit margin
-2,591.66%
566.44%

ARMP Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 177.42%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.29
-$0.40
-$0.10
-$0.86
-
Expected
-$0.28
-$0.32
-$0.38
-$0.31
-$0.35
Surprise
3.57%
25%
-73.33%
177.42%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Armata Pharmaceuticals stock

Buy or sell Armata Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing